EMA — authorised 28 June 2024
- Application: EMEA/H/C/005797
- Marketing authorisation holder: Valneva Austria GmbH
- Local brand name: Ixchiq
- Indication: Ixchiq is indicated for active immunisation for the prevention of disease caused by chikungunya virus (CHIKV) in individuals between 12 years older. The use of this vaccine should be in accordance with official recommendations.
- Pathway: PRIME
- Status: approved
The European Medicines Agency (EMA) approved IXCHIQ, a vaccine for active immunisation against chikungunya virus (CHIKV) disease. This approval was granted on 28 June 2024, under the PRIME expedited pathway. The vaccine is indicated for individuals aged 12 years and above, and its use should follow official recommendations.